ArticleThe journal of extra-corporeal technology2026
Strategic decision-making for redo cardiac surgical patients with biventricular heart failure - description of a surgical technique.
Article in The journal of extra-corporeal technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLeft ventricular assist devices (LVADs) play a critical role in managing end-stage heart failure (HF), serving as a bridge to transplantation (BTT) or as destination therapy (DT). Patients with prior mechanical valve replacements who later require LVAD support present unique surgical challenges, including increased thrombotic risk, hemodynamic mismatch, and prolonged operative time. To address these concerns, direct balloonexpandable transcatheter heart valve (B/Ex-THV) implantation offers a minimally invasive alternative for high-risk redo cases.
objectiveTo evaluate the feasibility, safety, and hemodynamic performance of direct B/Ex-THV implantation combined with HeartMate 3 LVAD in high-risk patients with prior mechanical valve surgery or native aortic valve disease.
methodsThis retrospective case series included 16 patients undergoing concomitant HeartMate 3 LVAD and direct B/Ex-THV implantation between April 2022 and October 2023. Nine patients received THVs anchored within prior mechanical prostheses (valve-in-frame), while seven underwent implantation into the native aortic annulus (valve-in-ring). Procedural metrics, hemodynamic outcomes, complications, and survival were analyzed.
resultsAll procedures were successfully completed. The valve-in-frame group demonstrated stable mid-term hemodynamics with low mean gradients (5.0 ± 1.3mmHg) and preserved effective orifice area. No significant paravalvular leak or structural deterioration was observed. At 30 days, 93.75% of patients survived; 12 and 24-month survival rates were both 75%. No valve migration, thrombosis, or hemolysis occurred. One patient who underwent valve-in-frame implantation subsequently underwent successful orthotopic heart transplantation 12 months later.
conclusionDirect B/Ex-THV implantation with concurrent LVAD surgery is a feasible and safe strategy in complex redo patients. It minimizes ischemic time, preserves hemodynamic function, and aligns with ISHLT recommendations, offering a promising approach for managing advanced HF in patients with previous valve interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.